Inhibitor effect of Janus kinase II in bleomycin-induced pulmonary fibrosis model Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016
Role of the TrkA receptor in experimental severe pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016
The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013
Effects of broad spectrum tyrosin kinase inhibitor on pulmonary circulation homeostasis Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017
Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
The effect of dasatinib, a novel tyrosine kinase inhibitor, on the regression of pulmonary fibrosis in mice Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014
Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
Proteasome function in lung fibrosis Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013
Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Lipoxin (LXA4 ) as a novel therapy for idiopathic pulmonary fibrosis Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014
Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016
Biochemical and functional characterization of lysyl oxidase like 2 (LOXL2) inhibitors Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Loss of CARM1 prolongs bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014